Network meta-analysis of novel targeted therapies for relapsed/refractory chronic lymphocytic leukemia.

ABSTRACT: The recent development of new antileukemic therapies (anti-CD20 monoclonal antibodies, Bruton tyrosine kinase inhbitors, phosphoinositide 3-kinase inhibitors, and B-cell lymyphoma-2 antagonists) improved the progression-free survival (PFS) compared with selected standard regimens in clinical trials for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Unfortunately, the relative efficacy of all possible therapeutic options remains unknown because there is no direct evidence for all possible comparisons. We aimed to compare the efficacy and safety of novel agents, chemotherapy, and immunotherapy using a Bayesian network meta-analysis (NMA). Systematic literature review with Bayesian NMA. An extensive systematic literature review of randomized clinical trials for relapsed

SUBMITTER: Monica M 

PROVIDER: S-EPMC11292688 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature